新検索ページはこちら
ログイン
お問い合わせ
（旧版）科学的根拠に基づく糖尿病診療ガイドライン 改訂第2版
書誌情報
引用文献
5．経口血糖降下薬による治療
文献
| 1） | United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310(6972):83-8. レベル1 |
| 2） | Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12. レベル3 |
| 3） | Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22(6):920-4. レベル3 |
| 4） | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53. レベル1 |
| 5） | Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25(1):10-6. レベル1＋ |
| 6） | Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89. レベル1 |
| 7） | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854-65. レベル1 |
| 8） | Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA. 1997;278(20):1663-9. レベル3 |
| 9） | Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-17. レベル2 |
| 10） | Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(2):CD003639. レベル1＋ |
| 11） | Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care. 1997;20(4):597-606. レベル2 |
| 12） | Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care. 1996;19(11):1194-9. レベル1 |
| 13） | Blaum CS, Velez L, Hiss RG, Halter JB. Characteristics related to poor glycemic control in NIDDM patients in community practice. Diabetes Care. 1997;20(1):7-11. レベル2 |
| 14） | DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541-9. レベル1 |
| 15） | Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care. 1999;22(1):33-7. レベル1＋ |
| 16） | Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(3):CD002966. レベル1＋ |
| 17） | Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 1994;121(12):928-35. レベル2 |
| 18） | 後藤由夫，馬場茂明，中川昌一，葛谷 健，平田幸正，赤沼安夫，坂本信夫，繁田幸男，垂井清一郎，兼子俊男，三村悟郎．α-glucosidase阻害薬AO-128のインスリン非依存型糖尿病に対する有用性 第3相二重盲検群間比較試験．医学のあゆみ．1992;160(12):943-71. レベル2 |
| 19） | Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, Edwards G, Johns D; GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28(3):544-50. レベル1 |
| 20） | 兼子俊男，馬場茂明，豊田隆謙，赤沼安夫，坂本信夫，繁田幸男，七里元亮，中野重行．インスリン抵抗性改善薬AD-4833の食事療法のみのインスリン非依存型糖尿病に対する臨床評価 プラセボを対照薬とした二重盲検比較試験．臨牀と研究．1997;74(6):1491-514. レベル2 |
| 21） | 兼子俊男，馬場茂明，豊田隆謙，赤沼安夫，坂本信夫，繁田幸男，七里元亮．インスリン非依存型糖尿病に対するAD-4833の長期投与時の臨床的有用性 第III相長期投与試験．臨牀と研究．1997;74(6):1589-613. レベル2 |
| 22） | Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605-11. レベル1 |
| 23） | 繁田幸男，葛谷 健，大森安恵，大橋靖雄，小坂樹徳．速効・短時間型血糖降下剤AY4166のインスリン非依存糖尿病に対する有用性 プラセボを対照とした第III相二重盲検群間比較試験．薬理と臨床．1997;7(5):729-54. レベル2－ |
| 24） | 小坂樹徳，菊池方利，垂井清一郎，繁田幸男，葛谷 健，赤沼安夫，豊田隆謙，大橋靖雄．速効・短時間型血糖降下剤AY4166のインスリン非依存糖尿病に対する長期投与試験．薬理と臨床．1997;7(5):797-818. レベル2 |
| 25） | Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 2000;23(2):202-7. レベル2 |
| 26） | United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med. 1998;128(3):165-75. レベル1 |
| 27） | Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-12. レベル1 |
| 28） | Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27(1):141-7. レベル1 |
| 29） | Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995;98(5):443-51. レベル2 |
| 30） | Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) Diabetes Care. 1999;22(6):960-4. レベル1 |
| 31） | Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. 1998;21(12):2050-5. レベル2 |
| 32） | 兼子俊男，馬場茂明，豊田隆謙，赤沼安夫，坂本信夫，繁田幸男，七里元亮，中野重行．インスリン抵抗性改善薬AD-4833のSU剤使用中のインスリン非依存型糖尿病に対する臨床評価 プラセボを対照薬とした二重盲検比較試験．臨牀と研究．1997;74(6):1515-39. レベル2 |
| 33） | Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005;48(6):1093-104. Epub 2005 May 12. レベル2 |
| 34） | 兼子俊男，鈴木晟時，井上 健，井上 穣，堺 秀人，金重秀明，武田 浩，沼野藤夫，内村 功，田中 明，神谷文雅，林 良成，森本真平，内田健三，木越俊和，中野 茂，北澤光孝，中井継彦，玉井利孝，笈田耕治，大澤仲昭，北岡治子，馬嶋素子，佐々木恵雲，藤村 紫，星 充，藤田峻作，松岡 瑛，谷内孝次，太田善介，槙野博史，西方賢一，島 健二，勢井雅子，松倉 茂，年森啓隆，黒瀬 健．インスリン抵抗性改善薬AD-4833のインスリン非依存型糖尿病に対するベイスン錠との併用投与における臨床評価 第III相非盲検試験．臨牀と研究．1997;74(6):1540-56. レベル4 |
| 35） | 垂井清一郎 ，小坂樹徳．α-グルコシダーゼ阻害剤投与中のインスリン非依存糖尿病患者に対するAY4166併用投与による臨床的有用性の検討．薬理と臨床．1997;7(5):767-84. レベル4 |
| 36） | Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23(11):1660-5. レベル1 |
| 37） | Jovanovic L, Hassman DR, Gooch B, Jain R, Greco S, Khutoryansky N, Hale PM. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract. 2004;63(2):127-34. レベル2 |
| 38） | Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. レベル1 |
| 39） | Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002 ;359(9323):2072-7. レベル1 |
| 40） | Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004;6(4):280-5. レベル4 |
| 41） | Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486-94. レベル1 |
